Sugi Predict

Sugi Predict / Compounds / SCHEMBL4877826

SCHEMBL4877826

SCHEMBL4877826

N=C(N)c1cccc(NC(C(=O)NCC(=O)N2CCSCC2)c2ccccc2OC2OC(CO)C(O)C(O)C2O)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC28A3 Q9HAS3 2/20 0.35
▸ F10 P00742 1/20 0.35
▸ HIF1A Q16665 1/20 0.33
▸ USP2 O75604 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ TNNI3 P19429 1/20 0.33
▸ TNNT2 P45379 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ TNNC1 P63316 1/20 0.33
▸ HKDC1 Q2TB90 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8271556 0.92 SLC28A3 (0.37) SLC28A3F10
SCHEMBL14269790 0.92 SLC28A3 (0.37) SLC28A3F10
SCHEMBL8271553 0.92 SLC28A3 (0.37) SLC28A3F10
SCHEMBL4876886 0.92 SLC28A3 (0.37) SLC28A3F10
SCHEMBL8271555 0.92 SLC28A3 (0.37) SLC28A3F10
SCHEMBL4870354 0.90 SLC28A3 (0.35) SLC28A3F10L3MBTL1
SCHEMBL4880081 0.89 SLC28A3 (0.36) SLC28A3HIF1AUSP2NPC1TNNI3
SCHEMBL16436970 0.88 TSHR (0.38) RAB9AKDM4EMEN1MAPTTHRB
SCHEMBL6778930 0.88 TSHR (0.38) RAB9AKDM4EMEN1MAPTTHRB
SCHEMBL6777768 0.88 F10 (0.41) SLC28A3F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051388-A1 Novel Compounds That Inhibit Factor Xa Activity MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2008-02-28 — — US disclosed
US-20080051388-A1 Novel Compounds That Inhibit Factor Xa Activity MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2008-02-28 — — US disclosed
US-20080051388-A1 Novel Compounds That Inhibit Factor Xa Activity MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2008-02-28 — — US disclosed
EP-1773855-A1 NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2007-04-18 — — EP disclosed
WO-2006008141-A1 NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2006-01-26 — — WO disclosed
WO-2006008141-A1 NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2006-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051388-A1 Novel Compounds That Inhibit Factor Xa Activity SERPINC1, TFPI, F11 SLC28A3 2331/4885F10 8/4885HIF1A 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.